Edwards Lifesciences Corp (NYSE:EW) plunged -3.58% during previous trade, a total of 3.63M shares exchanged hands compared with its average trading volume of 2.31M shares whereas its relative volume is 2.28. The stock has a market capitalization of $17.67B along with 213.81M outstanding shares. Stock’s intraday price range hit the peak level of $92.22 and touched the lowest level of $88.69.

Most recently Edwards Lifesciences Corp (NYSE:EW)’s price target was revised on 11/2/16 and according to 20 analysts stock’s price will reach at $122.10 during 52 weeks with standard deviation of 10.94. Stock’s minimum price target estimates has been figured out at $88 while the maximum price target forecast is established at $140, if we look at the price target with an optimistic approach it has upside potential of 58% from its latest closing price of $88.71.

Historically, if we look at price target revisions, three weeks ago Edwards Lifesciences Corp (NYSE:EW)’s price target was revised on 10/5/16 by the analysts, however the bullish price estimates of the stock set at $140 while the bearish estimates kept at $105 over the next one year. Stock’s 52-week target was retained at $126.93, the estimates indicates a standard deviation of 10.01.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.53. ABR value is precisely based on brokerage recommendations, where out of 18 brokerage recommendations 12 rate Edwards Lifesciences Corp (NYSE:EW) stock a Strong Buy, 2 rate the stocks of the company a Buy, 4 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 7/27/16 the stock of Edwards Lifesciences Corp (NYSE:EW) upgraded by BofA/Merrill from Neutral to Buy. However previously on 1/21/16 it was upgraded by Sun Trust Rbsn Humphrey from Neutral to Buy. A research note issued on 7/13/15 the stock was upgraded by Northland Capital from Market Perform to Outperform.

Edwards Lifesciences Corp (NYSE:EW) performance over the past one year plunged 15% whereas its year to date (YTD) performance indicated a bearish trend of 12.33%. During the last six months the stock slipped -21.48%. Quarterly performance of the company shows declining momentum of -21.48% while its last one month trend is negative with -25.56%. Stock’s weekly performance expressed down trend of -5.88%.

The company’s price sits -22.96% below from its 50-day moving average of $114.17 and -13.37% below from the stock’s 200-day moving average which is $108.70. Edwards Lifesciences Corp (NYSE:EW)’s shares are currently trading -27.14% away from the 52-week high price of $121.75 and +22.87% far from the 52-week low price of $72.20.

According to consensus agreement of 23 analysts Edwards Lifesciences Corp (NYSE:EW) will report earnings per share of $0.74 in their quarterly report and it is expected to announce the company’s results on 2/7/17. For the current quarter the company has high EPS estimates of $0.79 in contradiction of low EPS estimates of $0.71. However a year ago for the same quarter the company has reported $0.63 EPS. Current year EPS projections for Edwards Lifesciences Corp (NYSE:EW) set at $2.88 according to the sentiments of 23 analysts, while its lowest earnings estimates are $2.84 and highest earnings estimates are $2.94.

According to 21 analysts, Edwards Lifesciences Corp (NYSE:EW)’s revenue estimates for the current quarter are $786.51M meanwhile the company has high revenue estimates of $812M in contradiction of low revenue estimates of $766M. For the current year the company’s revenue estimates are $2.98B compared to low analyst estimates of $2.94B and high estimates of $3.04B according to the projection of 23 analysts.